Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments.
Papp
Julius Gy
JG
Division of Cardiovascular Pharmacology, Hungarian Academy of Sciences and Szeged University, Szeged, Hungary. PAPP@phcol.szote.u-szeged.hu.
Singh
Bramah N
BN
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011379:Prognosis
D000889:Anti-Arrhythmia Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003521:Cyclopropanes; C059921:tedisamil